bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes
Authors: Lee Young-Ho , Bae Hyun Cheol , Noh Kyung Hee , Song Kwon-Ho , Ye Sang-kyu , Mao Chih-Ping , Lee Kyung-Mi , Wu T.-C. , Kim Tae Woo
Published: April 2023

Supplementary Figure 3. Silencing of HIF-1α restores sensitivity of immune-resistant human cancer cells to lysis by tumor-specific human CTLs.
Supplementary Table S2 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Multivariable fixed model consisting of clinical ER, PgR, HER2, and Ki67 (IHC4), adjusted for one gene at a time with the end-point time to recurrence.
Supplementary Table S1 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Table S1. Relative intensity of SPARC staining
Supplementar yFigure S1 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Consort diagram
Supplementary Figure S4 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S4. B16 melanoma and EL-4 cells are Clever-1 negative.
Supplementary Table S3. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Table S3. Mutations found only in block Q tumor focus.
Figure S1 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S1. Representative images of FGFR1 GCN assayed by FISH in HNSCC cell lines.
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

Supplementary figure legend
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

Figure S3. Representative staining patterns of formalin-fixed, paraffinembedded primary ICC lesions with APM component-specific mAbs.
Supplementary Figure 6 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 6. Effects of external TG2 on fibroblasts and mouse pancreatic stellate cells.
Supplementary Figure 5. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

BET bromodomain inhibition leads to disruption of MYCN driven gene-expression programs even at high levels of MYCN. (a) Enrichment of the published gene expression signature for JQ1-treated human MYCN-amplified neuroblastoma cell lines (11) in differentially expressed genes in IMR-5 cells after treatment with OTX015, JQ1 or DMSO control. (b) Enrichment of the published gene expression signature for MYC target genes (16) in differentially expressed genes in IMR-5 cells after treatment with OTX015, JQ1 or DMSO control. (c) Enrichment of the published gene expression signature for JQ1-treated human MYCN-amplified neuroblastoma cell lines (11) in differentially expressed genes in mNB-A1 cells after treatment of with OTX015, JQ1 or DMSO control. (d) Enrichment of the published gene expression signature for MYC target genes (16) in differentially expressed genes in mNB-A1 cells after treatment with OTX015, JQ1 or DMSO control (* p < 0.05, ** p < 0.01, *** p < 0.001). (e) GSEA (version 2.0, Broad Institute) of differentially expressed genes in IMR5 cells after treatment with OTX015 or JQ1 using gene sets representing signatures of JQ1 as well as MYC target genes (11, 16).
Supplemental Materials and Methods from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplemental Materials and Methods. Additional details regarding methods for co-culture, immunohistochemistry, western blotting, immunofluorescence, proliferation assays, PCR, picrosirius red staining, and sircol and hydroxyproline assays.
Supplementary Table 1 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Table 1. Clinical characteristics of the 42 USC patients whose tissue specimens were utilized for HER2 immunohistochemical and FISH analyses.
Supplementary Figure 4 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure 4. Ki-67 staining of non-HER2 gene amplified USC xenografts. Unlike the HER2 amplified models, no changes in proliferation were seen upon treatment with lapatinib and/or trastuzumab in SPEC2 (A) and EnCa2 (B) xenografts. Tumors harvested at the completion of each in vivo treatment study were subjected to Ki-67 immunohistochemical analysis. Scale bars: 100 Ã‚Âµm.
All genes Hg19_BRD4_OTX from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

List of all genes from hg19 with changes in BRD4 binding using BRD4- ChIP-seq in IMR5 cells with changes after treatment with OTX015
Supplementary Figure 1 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure 1. HER2 expression levels in USC models. HER2 protein expression (A) and gene amplification (B) status of the USC cell line derived and patient derived xenografts that were utilized in this study, as assessed by IHC and FISH. HER2 protein over-expression as well as HER2 gene amplification were observed in ARK1, ARK2 and EnCa1 xenografts, while low HER2 protein expression and normal HER2 gene status were found in SPEC2 and EnCa2 xenografts.
Supplementary Materials from A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer
Authors: Hoogstins Charlotte E.S. , Tummers Quirijn R.J.G. , Gaarenstroom Katja N. , de Kroon Cor D. , Trimbos J. Baptist M.Z. , Bosse Tjalling , Smit Vincent T.H.B.M. , Vuyk Jaap , van de Velde Cornelis J.H. , Cohen Adam F. , Low Philip S. , Burggraaf Jacobus , Vahrmeijer Alexander L.
Published: April 2023

Supplementary Material and Methods: questionnaire for practical evaluation of OTL38 and the imaging system; description of immunohistochemistry and fluorescence microscopy. Fig. S1: Case report form (CRF) used to mark the location of a lesion found during surgery Fig. S2: Structure of OTL38 Fig. S3: CONSORT Flow diagram healthy volunteer study Fig. S4: Pharmacokinetics in blood plasma of healthy volunteers and patients. Fig. S5. CONSORT Flow diagram ovarian cancer patient study Fig. S6. Tumor-to-background ratio in ovarian cancer patients per dose group Fig. S7. FRα and β staining of ovarian carcinoma tissue and a metastatic lymph node Table S1. Listing of adverse events in the healthy volunteers study Table S2. Summary of pharmacokinetic parameters Table S3. Tumor-to-background ratio per dose group in ovarian cancer patients Table S4. Listing of adverse events in the patient study Table S5. Number and characteristics of lesions and lymph nodes identified with fluorescence
Supplementary Table 1 from Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Authors: Sinha Sutapa , Boysen Justin , Nelson Michael , Secreto Charla , Warner Steven L. , Bearss David J. , Lesnick Connie , Shanafelt Tait D. , Kay Neil E. , Ghosh Asish K.
Published: April 2023

Supplementary Table 1. Contains prognostic information of the CLL patients studied here
Supplementary Figure 1 from Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Authors: Sinha Sutapa , Boysen Justin , Nelson Michael , Secreto Charla , Warner Steven L. , Bearss David J. , Lesnick Connie , Shanafelt Tait D. , Kay Neil E. , Ghosh Asish K.
Published: April 2023

Supplementary Figure 1. BCR stimulation sensitizes CLL B-cells to BTK inhibitor induced apoptosis in vitro.
Supplementary Figure S3 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

complete targeted sequencing results
Supplementary data. Appendix 1. Members of The Danish Collaborative Research Group on Colorectal Cancer from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Authors: Rolff Hans Christian , Christensen Ib Jarle , Vainer Ben , Svendsen Lars Bo , Eefsen Rikke Løvendahl , Wilhelmsen Michael , Lund Ida Katrine , Høyer-Hansen Gunilla , Nielsen Hans Jørgen , Illemann Martin
Published: April 2023

Members of The Danish Collaborative Research Group on Colorectal Cancer
Supplementary Figure 3 from Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Authors: Chong Curtis R. , Bahcall Magda , Capelletti Marzia , Kosaka Takayuki , Ercan Dalia , Sim Taebo , Sholl Lynette M. , Nishino Mizuki , Johnson Bruce E. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Inhibition of Ba/F3 CD74-ROS1 proliferation
Supplementary figure legends from β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
Authors: San Millán Coral , Soldevilla Beatriz , Martín Paloma , Gil-Calderón Beatriz , Compte Marta , Pérez-Sacristán Belén , Donoso Encarnación , Peña Cristina , Romero Jesús , Granado-Lorencio Fernando , Bonilla Félix , Domínguez Gemma
Published: April 2023

Supplementary figure legends. Legend to the supplementary figures
Supplemental Figure 2 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
Authors: Ferrarotto Renata , Goonatilake Ruchitha , Young Yoo Suk , Tong Pan , Giri Uma , Peng Shaohua , Minna John , Girard Luc , Wang Yuehong , Wang Liguang , Li Lerong , Diao Lixia , Peng David H. , Gibbons Don L. , Glisson Bonnie S. , Heymach John V. , Wang Jing , Byers Lauren A. , Johnson Faye M.
Published: April 2023

Baseline gene and protein expression levels correlate with sensitivity to PLK1 inhibition in NSCLC cell lines. For NSCLC cell lines sensitive and resistant to all 3 drugs or to GSK461364 alone, baseline mRNA (48,804 probe sets) expression levels were compared using Illumina arrays (A), and baseline protein expression levels were compared using reverse-phase protein arrays (B). FDR, false-discovery rate.
Supplemental Figure S1 from Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
Authors: Brooks Samira A. , Khandani Amir H. , Fielding Julia R. , Lin Weili , Sills Tiffany , Lee Yueh , Arreola Alexandra , Milowsky Mathew I. , Wallen Eric M. , Woods Michael E. , Smith Angie B. , Nielsen Mathew E. , Parker Joel S. , Lalush David S. , Rathmell W. Kimryn
Published: April 2023

ccRCC histological morphologies.
Additional Table III from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Authors: Galimberti Sara , Luminari Stefano , Ciabatti Elena , Grassi Susanna , Guerrini Francesca , Dondi Alessandra , Marcheselli Luigi , Ladetto Marco , Piccaluga Pier Paolo , Gazzola Anna , Mannu Claudia , Monitillo Luigia , Mantoan Barbara , Del Giudice Ilaria , Della Starza Irene , Cavalli Marzia , Arcaini Luca , Tucci Alessandra , Palumbo Giuseppe Alberto , Rigacci Luigi , Pulsoni Alessandro , Vitolo Umberto , Boccomini Carola , Vallisa Daniele , Bertoldero Giovanni , Gaidano Gianluca , Musto Pellegrino , Petrini Mario , Federico Massimo
Published: April 2023

Cox proportional hazard Models for PFS: role of MRD-negativity after 24 month of follow-up.
Supplementary Figure 1 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Figure 1. CONSORT diagram
Supplementary Methods and Materials, Figure Legend from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Methods and Materials, Figure Legend
Supplementary Figure S3 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S3. Effects of C086 on cell cycle progression.
Supplemental Figure S2 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
Authors: Bowers Jacob S. , Nelson Michelle H. , Kundimi Sreenath , Bailey Stefanie R. , Huff Logan W. , Schwartz Kristina M. , Cole David J. , Rubinstein Mark P. , Paulos Chrystal M.
Published: April 2023

Supplemental Figure S2. Granulocytic MDSCs are transiently increased over monocytic MDSCs in tumor-bearing mice given increasing doses of TBI.
Supplementary Fig. S5 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S5. Validation of redundant APC mutations. A, For one case (CRC2), two redundant APC mutations are validated by Sanger sequencing. One nonsense mutation (C>T; left) and one frameshift indel (AG>A; right) are shown for seven regional biopsies for the given case. For one primary case (CRC2-P1), the nonsense mutation is not observed, consistent with the metastasis-clonal presentation of this mutation. B, The copy number changes of the entire chromosome 5 are shown for seven regional biopsies. Entire loss of chromosome 5 is observed for CRC-P1. APC locus is incidated with a red dotted line.
Supplementary Fig. S3 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S3. Allele frequencies of spatial mutation catalogs. A, The mutant allele frequencies are shown for the mutations in the five spatial categories. B, Mutant allele frequencies (y-axis) are shown for the total number of mutations observed in the biopsies from primary and metastatic lesions with significantdifference between them.
Supplemental Figure 3 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure with metabolic data
Supplementary Figure 6 from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

Inhibition of PTEN enhanced the activation of AKT and rescued the effect of miR-374b on cell proliferation and cell apoptosis
Supplementary Figure 5 from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

The effect of Î²-catenin on the roles of miR-374b in T-LBL cells
Supplementary Figure 2 from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

Depletion of miR-374b promoted cell proliferation and suppressed serum starvation-induced apoptosis in T-LBL cells
Supplementary Figure 1 from Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Authors: Kurose Koji , Ohue Yoshihiro , Wada Hisashi , Iida Shinsuke , Ishida Takashi , Kojima Takashi , Doi Toshihiko , Suzuki Susumu , Isobe Midori , Funakoshi Takeru , Kakimi Kazuhiro , Nishikawa Hiroyoshi , Udono Heiichiro , Oka Mikio , Ueda Ryuzo , Nakayama Eiichi
Published: April 2023

Pharmacokinetic (PK) analysis after KW-0761 infusions in solid cancer patients.
Legends for Supplementary Figures from Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Authors: Kurose Koji , Ohue Yoshihiro , Wada Hisashi , Iida Shinsuke , Ishida Takashi , Kojima Takashi , Doi Toshihiko , Suzuki Susumu , Isobe Midori , Funakoshi Takeru , Kakimi Kazuhiro , Nishikawa Hiroyoshi , Udono Heiichiro , Oka Mikio , Ueda Ryuzo , Nakayama Eiichi
Published: April 2023

Supplementary Figure 1. Pharmacokinetic (PK) analysis after KW-0761 infusions in solid cancer patients. Supplementary Figure 2. Clinical course of 3 NSCLC patients evaluated as SD at 12 weeks after treatment. Supplementary Figure 3. The changes in the specific populations in PBMCs, lymphocytes and CD4 T-cells. Supplementary Figure 4. Antibody response and CD4 and CD8 T-cell responses during treatment.
Supplementary Table 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Authors: Hombrink Pleun , Hassan Chopie , Kester Michel G.D. , Jahn Lorenz , Pont Margot J. , de Ru Arnoud H. , van Bergen Cornelis A.M. , Griffioen Marieke , Falkenburg J.H. Frederik , van Veelen Peter A. , Heemskerk Mirjam H.M.
Published: April 2023

Supplementary Table 2. MiHA validation scores
Supplementary Materials and Methods from Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy
Authors: Hayashi Tetsutaro , Gust Kilian M. , Wyatt Alexander W. , Goriki Akihiro , Jäger Wolfgang , Awrey Shannon , Li Na , Oo Htoo Zarni , Altamirano-Dimas Manuel , Buttyan Ralph , Fazli Ladan , Matsubara Akio , Black Peter C.
Published: April 2023

The lists of antibodies, primers and patients characteristics and detailed information of methods were described in Supplementary Material and Methods.
Supplementary Tables 1-3. from SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer
Authors: Bell Erica Hlavin , Chakraborty Arup R. , Mo Xiaokui , Liu Ziyan , Shilo Konstantin , Kirste Simon , Stegmaier Petra , McNulty Maureen , Karachaliou Niki , Rosell Rafael , Bepler Gerold , Carbone David P. , Chakravarti Arnab
Published: April 2023

Supplementary Table 1. Univariate analysis of SMARCA4 expression in the Director's Challenge Study. Supplementary Table 2. Log-rank analysis of SMARCA4 expression for observation vs adjuvant cisplatin/vinorelbine in NSCLC within the JBR.10 trial. Supplementary Table 3. Univariate analysis of SMARCA4 expression in the JBR.10 trial.
Supplemental Figure 4 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure 4. Viability of PLC/PRF/5 cells after treatment with bortezomib.
Supplementary Tables S2-4 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Authors: Hurley Paula J. , Sundi Debasish , Shinder Brian , Simons Brian W. , Hughes Robert M. , Miller Rebecca M. , Benzon Benjamin , Faraj Sheila F. , Netto George J. , Vergara Ismael A. , Erho Nicholas , Davicioni Elai , Karnes R. Jeffrey , Yan Guifang , Ewing Charles , Isaacs Sarah D. , Berman David M. , Rider Jennifer R. , Jordahl Kristina M. , Mucci Lorelei A. , Huang Jessie , An Steven S. , Park Ben H. , Isaacs William B. , Marchionni Luigi , Ross Ashley E. , Schaeffer Edward M.
Published: April 2023

Supplementary Table S2 shows bivariate and multivariable analyses of germline ASPN D13/14 compared to ASPN D13/13 for lymph node involvement and metastatic recurrence. Supplementary Table S3 show bivariate analyses of ASPN D genotypes/alleles for biochemical recurrence. Supplementary Table S4 shows multivariable analyses of ASPN D13/14 for biochemical recurrence.
Supplementary materials from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary materials
Supplementary figure 3 and 4 from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary figure 3 and 4. Figure S3: Generation and specificity of 6H5mAx. Figure. S4: Generation of EL4-HERV-K and specificity of HERV-K env-specific CAR+ T cells.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 3 - Proliferation and colony formation assays of gastric cancer monolayer cells and spheroid cells.
Supplementary Methods from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Methods
Supplementary Figure 4 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 4. Vaccinia virus coat protein expression in pancreatic tumors of KPC mice
Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3 from Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Authors: Paweletz Cloud P. , Sacher Adrian G. , Raymond Chris K. , Alden Ryan S. , O'Connell Allison , Mach Stacy L. , Kuang Yanan , Gandhi Leena , Kirschmeier Paul , English Jessie M. , Lim Lee P. , Jänne Pasi A. , Oxnard Geoffrey R.
Published: April 2023

Supplemental Figure 1: Comparison of targeted sequencing of cfDNA using standard hybridization selection versus Resolution methods. (A) UCSC genome browser depiction of read coverage in the TP53 vicinity. The coverage track representing hybridization selection of cfDNA was created by mapping the reads from sample SRR1197557 of Newman et al 2014. The other coverage track represents unique reads from Sample 511 in this paper. The off-target noise outside of the TP53 gene is higher in SRR1197557 compared with Sample 511. (B) Genome-wide calculation of off-target versus on-target coverage for the two samples. The percentage of read coverage overlapping the declared target regions (widened by an extra 100 nucleotides on each side) was calculated using bedtools. Supplemental Figure 2: Sensitivity of mutant allele detection as a function of dilution. A total of four gene fusions (orange open squares), thirteen point mutations (black circles) and one indels (orange open squares), were assayed at varying mutant allele concentrations (Supplemental Table 1). All 18 lesions were detected in the 2.5%, 1.0%, and 0.4% pools, while fourteen out of the 18 were detected at 0.1%. We expect gene fusions to be more difficult to detect because adequate sequence coverage demands a larger assay footprint than point mutations and probe orientation is unidirectional rather than bidirectional. Consistent with this expectation, the ROS1 fusion in cell line HCC78 and the ALK fusion in cell line H3122 were underrepresented. Supplemental Figure 3: Schematic of predicted genomic junctions for 5 translocations identified in plasma specimens.
Supplementary Figure S5 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S5. Representative western blot of two independent experiments characterizing the impact PF-05212384 has on ATM and DNA-PKc autophosphorylation and total protein levels as a function PF-05212384 (10 μM) treatment time following irradiation (7.5 Gy) in exponentially growing UMSCC1 and UMSCC46 HNSCC cells (A).
Supplementary Figure S5 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Signaling consequences of afatinib monotherapy and comparison with lapatinib: Duplicate blots for HER receptors.
Supplementary Fig. 1 from Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Authors: Gebhardt Christoffer , Sevko Alexandra , Jiang Huanhuan , Lichtenberger Ramtin , Reith Maike , Tarnanidis Kathrin , Holland-Letz Tim , Umansky Ludmila , Beckhove Philipp , Sucker Antje , Schadendorf Dirk , Utikal Jochen , Umansky Viktor
Published: April 2023

Frequencies and NO production by moMDSCs from non-responders (A) and responders (B) after the first infusion of ipilimumab.
Supplementary Tables 1-6 from Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells
Authors: Venugopal Chitra , Hallett Robin , Vora Parvez , Manoranjan Branavan , Mahendram Sujeivan , Qazi Maleeha A. , McFarlane Nicole , Subapanditha Minomi , Nolte Sara M. , Singh Mohini , Bakhshinyan David , Garg Neha , Vijayakumar Thusyanth , Lach Boleslaw , Provias John P. , Reddy Kesava , Murty Naresh K. , Doble Bradley W. , Bhatia Mickie , Hassell John A. , Singh Sheila K.
Published: April 2023

Supplementary Tables 1-6. Supplementary Table 1: Clinico-pathological demographics of CD133high and CD133low GBM; Supplementary Table 2: Positive and negative correlation probe sets present in CD133-signature; Supplementary Table 3: Drug targets acquired from CD133 gene signature connectivity map; Supplementary Table 4: qRT-PCR Primers; Supplementary Table 5: Genes used to complete network analysis; Supplementary Table 6: Molecular Subtypes of GBM samples used
Supplementary Figure 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Integrin α3 or GALNT1 knockdown inhibits bladder cancer growth.
Supplementary Figure 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

BCMab1 recognizes the aberrantly glycosylated Integrin α3 on bladder cancer and GALNT1 silencing impairs BCMab1 staining.
Figure S3 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Authors: Kummar Shivaani , Oza Amit M. , Fleming Gini F. , Sullivan Daniel M. , Gandara David R. , Naughton Michael J. , Villalona-Calero Miguel A. , Morgan Robert J. , Szabo Peter M. , Youn Ahrim , Chen Alice P. , Ji Jiuping , Allen Deborah E. , Lih Chih-Jian , Mehaffey Michele G. , Walsh William D. , McGregor Paul M. , Steinberg Seth M. , Williams P. Mickey , Kinders Robert J. , Conley Barbara A. , Simon Richard M. , Doroshow James H.
Published: April 2023

Supplemental Figure S3. Heat map of gene expression profiling results with clusters for treatment response of 55 patients and 203 DNA repair genes.
Supplemental Figure 2 from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 2. RB deficiency promotes enhanced apoptotic pathway in response to ionizing radiation
Supplementary Table S2 from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Supplementary Table S2. Table providing detailed survival results for univariate and multivariate analyses of association of subtype classification with overall survival.
Supplemental Figure 1 (Transformation Assays) and Supplemental Figure 2 (Colony Assays) from The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I
Authors: Maxson Julia E. , Luty Samuel B. , MacManiman Jason D. , Paik Jason C. , Gotlib Jason , Greenberg Peter , Bahamadi Swaleh , Savage Samantha L. , Abel Melissa L. , Eide Christopher A. , Loriaux Marc M. , Stevens Emily A. , Tyner Jeffrey W.
Published: April 2023

Supplemental Figure 1 showing the relative transforming capacity of CSF3R mutants; Supplemental Figure 2 showing a control experiment with the sensitivity of BCR-ABL to ruxolitinib and dasatinib.
supplemental figure legend from Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Authors: Vassilakopoulou Maria , Avgeris Margaritis , Velcheti Vamsidhar , Kotoula Vassiliki , Rampias Theodore , Chatzopoulos Kyriakos , Perisanidis Christos , Kontos Christos K. , Giotakis Aris I. , Scorilas Andreas , Rimm David , Sasaki Clarence , Fountzilas George , Psyrri Amanda
Published: April 2023

supplemental figure legend
Supplementary Appendix 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Appendix 2. Spike-in experiment with Salmonella typhimurium
Supplementary Table S1 from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Table S1. dCK positivity of nuclei of xenograft tumour, stroma and vasculature.
Supplementary Methods from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Authors: Wouters Maartje C.A. , Komdeur Fenne L. , Workel Hagma H. , Klip Harry G. , Plat Annechien , Kooi Neeltje M. , Wisman G. Bea A. , Mourits Marian J.E. , Arts Henriette J.G. , Oonk Maaike H.M. , Yigit Refika , de Jong Steven , Melief Cornelis J.M. , Hollema Harry , Duiker Evelien W. , Daemen Toos , de Bruyn Marco , Nijman Hans W.
Published: April 2023

Supplementary Methods
Supplementary Methods from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figures S1-7 from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Figures S1-7. Supplementary Figure S1: Gene expression profiles of classic biomarkers in matched tumour samples from 3 patients. Supplementary Figure S2: Network map showing the enriched KEGG pathways from upregulated differentially expressed genes (DEGs). Supplementary Figure S3: Network map showing the enriched KEGG pathways from downregulated differentially expressed genes (DEGs). Supplementary Figure S4: Protein expression in matched primary and metastatic tissue from endocrine treated breast cancer patients. Supplementary Figure S5: Phosphorylated mTOR signaling in endocrine resistant breast cancer tumours. Supplementary Figure S6: Interaction plot showing functional roles for 21 genes commonly upregulated in metastatic liver tumours of all three patients. Supplementary Figure S7: Genes upregulated in liver metastases are also strongly expressed in breast metastases to the brain.
Supplemental Figure 1 Part 3 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 1 Part 3. Quantification of metabolomic data continued.
Supplemental Figure 1 Part 2 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 1 Part 2. Quantification of metabolomic data continued.
Supplemental Figure 1 Part 1 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 1 Part 1. Quantification of metabolomic data
Supplemental Figure S4 from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression of ERK and p38 and effect of ERK and p38 inhibition on migration and invasion.
Suppl Fig 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 3. Analysis of PI3K/AKT/mTOR pathway activity in ALL cell lines.
Table S1 from Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Authors: Ben-Josef Edgar , George Asha , Regine William F. , Abrams Ross , Morgan Meredith , Thomas Dafydd , Schaefer Paul L. , DiPetrillo Thomas A. , Fromm Mitchel , Small William , Narayan Samir , Winter Kathryn , Griffith Kent A. , Guha Chandan , Williams Terence M.
Published: April 2023

Table S1. Distribution of GSK3β Expression (fluorescence intensity units) for Patients Entered on RTOG 97-04 (n=163)
Figure S1 legend from Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Authors: Ben-Josef Edgar , George Asha , Regine William F. , Abrams Ross , Morgan Meredith , Thomas Dafydd , Schaefer Paul L. , DiPetrillo Thomas A. , Fromm Mitchel , Small William , Narayan Samir , Winter Kathryn , Griffith Kent A. , Guha Chandan , Williams Terence M.
Published: April 2023

Legend for Figure S1
Table S2 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Table S2. Combination index (CI) values for OVCAR5 and SKOV3 cell lines treated with Carboplatin and Doxorubicin, Abraxane, Docetaxel or Paclitaxel.
Supplementary Figures S3qc and S4qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Extreme limiting dilution assay AND Expression of signature neural stem-like genes.
Figure S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Figure S1. Lipoplatin activity in A2780 and A2780cis cells
Supplementary Figure S6qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Confirmatory subclone selection experiments applying clinical sample BN046.
Supplementary Figure 1 from First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Authors: Munster Pamela , Aggarwal Rahul , Hong David , Schellens Jan H.M. , van der Noll Ruud , Specht Jennifer , Witteveen Petronella O. , Werner Theresa L. , Dees E. Claire , Bergsland Emily , Agarwal Neeraj , Kleha Joseph F. , Durante Michael , Adams Laurel , Smith Deborah A. , Lampkin Thomas A. , Morris Shannon R. , Kurzrock Razelle
Published: April 2023

Duration of therapy and best objective response in the expansion cohorts (Breast, Bladder, Renal, and Endometrial Cancer)
Supplementary Figure S2qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Maintenance of patient- and disease-specific genetic alterations ex vivo.
Supplemental Figure 5 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

CEBPD expression is correlated with pEGFR, pSTAT3 and ABCB1 expression in UCUB patients. Immunostaining on representative case developed metastatic disease (Case-45, Left panel) exhibits high pEGFR, pSTAT3, CEBPD, and ABCB1 expression; while the case with superior outcome (Case-32, Right panel) shows low expression of these proteins.
Supplementary figure legends from Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Authors: Hawinkels Lukas J.A.C. , de Vinuesa Amaya Garcia , Paauwe Madelon , Kruithof-de Julio Marianna , Wiercinska Eliza , Pardali Evangelia , Mezzanotte Laura , Keereweer Stijn , Braumuller Tanya M. , Heijkants Renier C. , Jonkers Jos , Löwik Clemens W. , Goumans Marie-José , ten Hagen Timo L. , ten Dijke Peter
Published: April 2023

Supplementary figure legends
Supplemental Figure 2 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Levels of CEBPD associates with STAT3 activity in gefitinib-treated CDDP-resistant NTUB1/P (NTP) cells. A, Western blot analysis was conducted with lysates from NTP cells treated with gefitinib following various time courses and blotted with specific antibodies. B, gefitinib and S3I-201 attenuate expression of phosphorylation of STAT3 (pY705) and CEBPD in J82 cells. Cells were treated with CDDP alone or in combination with gefitinib or S3I-201 for 24 h. Western blot was conducted with indicated antibodies, respectively.